Skip Navigation
Print This Page
Share this page: More

Search Results

PACCT1 Program for the Assessment of Clinical Cancer Tests: Trial Assigning IndividuaLized Options for Treatment: The TAILORx Trial
Protocol Number:
Phase III
Antonio Wolff
Many women with early-stage breast cancer are advised to receive chemotherapy in addition to hormonal therapy, yet research has not shown that chemotherapy benefits all of them equally. The TAILORx trial will use the Oncotype DX test results to assign patients to either 1)chemotherapy + hormonal therapy or 2)hormonal therapy alone based on their Oncotype DX Recurrence Score(RS).
- women with invasive breast cancer that is estrogen and/or progesterone receptor positive - negative lymph nodes - no Her2+ breast cancer - tumor size 1.1-5 cm (or 5 mm-1.0 cm if unfavorable features) - must be agreeable to initiate standard chemotherapy and hormonal therapy as adjuvant treatment - must be between 18-75 years old - good physical condition and good organ function - no prior chemo or radiation for this malignancy - no prior history of breast cancer or other prior malignancies within the past 5 yrs
Pts with RS of 11-25 will be randomized to receive either chemo/hormonal therapy or hormonal therapy alone. The choice of which type of chemotherapy and hormonal therapy is given will be determined by you and your physician.
Last Update
07/26/2014 04:02 AM

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers


Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424



© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer